---
schema_version: "secwatch.filing_event.v1"
accession: "0001576885-23-000065"
form_type: "8-K"
ticker: "ABOS"
cik: "0001576885"
company_name: "Acumen Pharmaceuticals, Inc."
filed_at: "2023-11-13T23:59:59+00:00"
generated_at: "2026-06-08T05:08:37.263203+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Acumen updates ACU193 Phase 1 subcutaneous trial to mid-2024; secures $50M credit facility

## Summary
- Projected mid-2024 initiation of Phase 1 subcutaneous trial for ACU193.
- Reported results from recent FDA interaction regarding ACU193 development.
- Additional CSF biomarker data from Phase 1 INTERCEPT-AD trial presented.
- New credit facility of up to $50 million from K2 HealthVentures.

## SEC filing metadata
- accession: 0001576885-23-000065
- form_type: 8-K
- ticker: ABOS
- cik: 0001576885
- company_name: Acumen Pharmaceuticals, Inc.
- filed_at: 2023-11-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1576885/000157688523000065/0001576885-23-000065-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1576885/000157688523000065/abos-20231113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001576885-23-000065
- JSON: https://secwatch.observer/filing/0001576885-23-000065.json
- Plain text: https://secwatch.observer/filing/0001576885-23-000065.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.